News and Trends 21 Jul 2022 Almirall launches new call to find innovative therapies for skin diseases A new call for new therapies to treat skin diseases has been launched by global Spanish-based biopharmaceutical company, Almirall, S.A. This is the seventh call through AlmirallShare – an open innovation platform for proposals to establish collaborations in dermatological research. The aim of this year’s edition is to find new partnership opportunities for assets in […] July 21, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 20 Jul 2022 BigHat Biosciences raises $75M to design safer, more effective antibodies A company developing safer, more effective antibody therapies for patients using machine learning and synthetic biology, today (July 20) announced it has raised $75 million in funding. BigHat Biosciences’ series B funding round was led by Section 32 with participation from new investors Amgen Ventures, Bristol Myers Squibb, Quadrille Capital, Gaingels, GRIDS Capital and others. […] July 20, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 20 Jul 2022 Iron protein can now be captured thanks to technology developed by NaviGo An iron-storing protein can now be captured thanks to the successful development of a Precision Capturing affinity resin. Ferritin, an intracellular protein, is released into the bloodstream in small amounts where it acts as an iron carrier. Protein engineering company and developer of affinity ligands for custom chromatography solutions, NaviGo Proteins GmbH, announced today (July […] July 20, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 20 Jul 2022 Plant-based nylon addressing urgent need for sustainable materials Global brands need to take action by using sustainable materials with traceable and transparent supply chains, the CEO of a US biotech company says. Genomatica (Geno) alongside longtime collaborator Aquafil has just completed the first demonstration scale production runs for plant-based nylon-6. Christopher Schilling, Geno CEO says: “Now, more than ever, global brands are taking […] July 20, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 20 Jul 2022 Business looks to grow life sciences sector in China A Shanghai business says its top priority is to carry on contributing to the rapid growth of the life sciences sector in China. The ATLATL Center for Innovation & Research is a biopharma research-based open platform that builds laboratories and office spaces equipped with professional research and development (R&D) services, lab facilities and operations management. […] July 20, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 19 Jul 2022 Good news for Destiny Pharma’s nasal gel to combat life-threatening infections Clinical stage biotech company, Destiny Pharma, announced today (July 19) a positive update from the U.S. Food and Drug Administration (FDA) on its XF-73 nasal gel phase 3 development plans. The FDA has clarified the phase 3 and U.S. registration pathway for the gel for the prevention of post-surgical staphylococcal infections, and this feedback enables […] July 19, 2022 - 5 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 19 Jul 2022 CN Bio opens new lab to meet increasing market demand for organ-on-chip research services New laboratory facilities have been opened today (July 19) at UK organ-on-chip company CN Bio to meet market demand. The Cambridge-based company’s laboratory space has doubled in response to an increasing need for services as the technology gains traction within drug discovery and development programs. Microphysiological systems CN Bio concentrates on designing single and multi-organ […] July 19, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 19 Jul 2022 Spider silk to be produced for Kraig Biocroft Laboratories after agreement signed Hundreds of kilograms of spider silk will be produced per month after Kraig Biocraft Laboratories joined forces with a contractor. Kraig Labs is a biotechnology company and wants to focus on the development and commercialization of spider silk and expects to achieve its target production levels as early as the first quarter of next year […] July 19, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 18 Jul 2022 Positive results for drug combination used to treat rare blood cancer Exploratory analysis of anti-cancer drug, navitoclax, combined with ruxolitinib – a medication for the treatment of intermediate or high-risk myelofibrosis (MF) – has given positive results in a study. The data, announced by US biopharma company, AbbVie, comes from cohort 3 of a phase 2 REFINE study in Janus kinase (JAK) inhibitor naïve patients with […] July 18, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
More News! 18 Jul 2022 Purespring Therapeutics and SwanBio Therapeutics announce agreement for use of FunSel screening platform A licensing agreement for use of the FunSel screening platform has been announced by Purespring Therapeutics and SwanBio. Under the terms of the agreement, SwanBio will license the FunSel screening platform from Purespring to explore new targets for early-stage pipeline programs. SwanBio will have the option to develop any targets identified and to own and […] July 18, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 18 Jul 2022 Trial for drug targeting cancerous tumors begins in China A phase 1 trial to investigate a drug for treating people with advanced malignant neoplasms has begun in China. HUTCHMED announced the trial of anti-CD47 monoclonal antibody HMPL-A83 on Friday (July 15). It is the thirteenth innovative oncology drug candidate discovered in-house by HUTCHMED and it is the company’s second large molecule drug candidate to […] July 18, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 18 Jul 2022 First-ever Marketing Authorization Application for biosimilar targeting MS filed An international biotech, with headquarters in Amsterdam, has announced that the European Medicines Agency (EMA) has accepted the first-ever Marketing Authorization Application (MAA) for its biosimilar product. Polpharma Biologics, which is dedicated to the development of biosimilars, announced on Friday (July 15) that natalizumab, similar to Tysabri, which treats multiple sclerosis, has been accepted as […] July 18, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email